Compare Cytokinetics Inc (CYTK) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs KKR & Co Inc — how do they compare? Cytokinetics Inc trades at $62.79 (market cap $8.62B), while KKR & Co Inc trades at $91.07 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 9.3× Cytokinetics Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and KKR & Co Inc for 67 Days on average.
| CYTK | KKR | |
|---|---|---|
Market Cap | $8.62B | $80.39B |
Volume | 2,594,626 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $87.26 | $142.75 |
52-Week Low | $54.76 | $83.88 |
Typical Hold Time | 19 Days | 67 Days |
Enterprise Value | $8.72B | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
KKR trades at $92.48, up 3.13% today, showing strong momentum after recent earnings beats. The stock faces bearish technical signals but maintains solid fundamentals with $19.21B revenue and $2.37B net income for 2025. Recent business developments include strategic joint ventures and asset sales, while analyst consensus remains overwhelmingly bullish with an average price target of $123.30.
KKR presents a compelling investment opportunity with strong earnings momentum and institutional support, though technical indicators suggest near-term caution. The company's diversified investment portfolio and active deal flow provide growth catalysts, balanced by market volatility risks and the cyclical nature of private equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
